Cutaneous Adverse Drug Eruption: Identifiable with Drug Patch Testing?

Drug patch testing in cutaneous drug allergic patient

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20200107003

Enrollment

Registered

2020-01-07

Start date

2016-02-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous drug eruption Drug patch test

Interventions

The study population consisted of patients with a diagnosis of CADRs including DRESS, MP rash, FDE, lichenoid drug eruption, exfoliative dermatitis, SJS/TEN and AGEP

Diagnostic

Cutaneous drug eruption group

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patient with cutaneous drug eruption including all delayed type drug eruption 1 DRESS 2 AGEP 3 Morbiliform drug rash 4 lichenoid drug eruption 5 fixed drug eruption 6 SJS , TEN

Exclusion criteria

Exclusion criteria: Patient with immunosuppressive agent Patient with immediated type drug hypersensitivity such as urticaria and anaphylaxia

Design outcomes

Primary

Measure	Time frame
positive drug patch test 48-96 hours drug patch test	—

Secondary

Measure	Time frame
safety 48-96 hours drug patch test	—

Countries

Thailand

Contacts

Public ContactSupitchaya Thaiwat

Phramongkulkloa collage of medicine

Thaiwat@pcm.ac.th0629792463

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026